HF
HRMY icon

HRT Financial’s Harmony Biosciences HRMY Stock Holding History

HRT Financial’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.47M Sell
177,674
-148,201
-45% -$4.68M 0.01% 1001
2026
Q1 		$9.13M Buy
325,875
+170,800
+110% +$5.6M 0.02% 660
2025
Q4 		$5.8M Buy
+155,075
New +$5.1M 0.02% 709
2025
Q2 		– Sell
-98,669
Closed -$3.27M – 3021
2025
Q1 		$3.27M Buy
+98,669
New +$3.54M 0.02% 601
2024
Q4 		– Sell
-54,066
Closed -$2.16M – 2746
2024
Q3 		$2.16M Buy
54,066
+22,286
+70% +$783K 0.01% 855
2024
Q2 		$958K Buy
+31,780
New +$956K 0.01% 1038
2023
Q2 		– Sell
-8,309
Closed -$271K – 2796
2023
Q1 		$271K Buy
+8,309
New +$378K ﹤0.01% 1771
2021
Q1 		– Sell
-33,812
Closed -$1.22M – 2874
2020
Q4 		$1.22M Buy
+33,812
New +$1.36M 0.02% 516

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's HRMY Position: Q2 2026 in Review

HRT Financial reduced its Harmony Biosciences (HRMY) stake by 45% in Q2 2026, selling an estimated $4.68M and leaving 177,674 shares worth $6.47M. The position accounts for 0.01% of the portfolio, ranked #1001.

HRT Financial first reported a position in HRMY in Q4 2020 and has held it in 8 quarters since. The position peaked at $9.13M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • HRT Financial held 177,674 shares of Harmony Biosciences worth $6.47M as of Q2 2026.
  • HRT Financial sold 148,201 Harmony Biosciences shares in Q2 2026, an estimated $4.68M.
  • Harmony Biosciences made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1001 holding.
  • HRT Financial first reported a position in Harmony Biosciences in Q4 2020 and has held it in 8 quarters since.
  • HRT Financial's Harmony Biosciences position peaked at $9.13M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.